A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer
Phase 2
Terminated
NCT04916002
| Condition | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma, Triple Negative Breast Cancer |
|---|
| Phase | Phase 2 |
|---|
| Sponsor | Regeneron Pharmaceuticals |
|---|
| Status | Terminated |
|---|
| Enrollment | 77 participants |
|---|
| Interventions | vidutolimod, cemiplimab |
|---|
| Start date | Nov 30, 2021 |
|---|
| Completion date | Oct 31, 2024 |
|---|
| Results posted | Dec 5, 2025 |
|---|
Summary
The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main questions it aims to answer are: * How many participants' cancers respond to vidutolimod together with cemiplimab? * Is vidutolimod together with cemiplimab safe and well-tolerated? * How well does vidutolimod together with cemiplimab treat participants' cancer? Participants will receive trial treatment for up to 2 years. 30 days after stopping treatment, participants will have a follow-up visit. After that visit, the trial staff will continue to follow up with participants about every 3 months, until the trial ends.
Objective Response Rate (ORR)
Up to 31.5 Months · Percentage of participants
| Cohort A1: CMP-001+Cemiplimab for CSCC | 44.0 Percentage of participants |
|---|
| Cohort A2: CMP-001+Cemiplimab for CSCC | 5.3 Percentage of participants |
|---|
| Cohort B1: CMP-001+Cemiplimab for MCC | 46.2 Percentage of participants |
|---|
| Cohort B2: CMP-001+Cemiplimab for MCC | 6.3 Percentage of participants |
|---|
| Cohort D: CMP-001+Cemiplimab for BCC | 25.0 Percentage of participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.